Literature DB >> 29209639

Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer.

Samantha M Bevill1, Jon S Zawistowski1, Gary L Johnson1.   

Abstract

Kinase inhibitors targeting the mitogen/extracellular signal-regulated kinase kinase (MEK)- extracellular signal related kinase (ERK) signaling pathway have limited durability in inhibiting growth of triple-negative breast cancer. We defined genome wide enhancer remodeling following MEK inhibition capable of driving adaptive gene transcription. Targeting positive elongation factor (P-TEFb) transcriptional regulatory complex members can block enhancer remodeling making the response to MEK-ERK inhibition durable.

Entities:  

Keywords:  Adaptive resistance; BRD4; MEK inhibition; P-TEFb complex; enhancer remodeling

Year:  2017        PMID： 29209639      PMCID： PMC5706954          DOI： 10.1080/23723556.2017.1300622

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  7 in total

1.  Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.

Authors:  Laura A Jaenicke; Björn von Eyss; Anne Carstensen; Elmar Wolf; Wenshan Xu; Ann Katrin Greifenberg; Matthias Geyer; Martin Eilers; Nikita Popov
Journal:  Mol Cell       Date:  2015-12-10       Impact factor: 17.970

2.  Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Authors:  Jon S Zawistowski; Samantha M Bevill; Daniel R Goulet; Timothy J Stuhlmiller; Adriana S Beltran; Jose F Olivares-Quintero; Darshan Singh; Noah Sciaky; Joel S Parker; Naim U Rashid; Xin Chen; James S Duncan; Martin C Whittle; Steven P Angus; Sara Hanna Velarde; Brian T Golitz; Xiaping He; Charlene Santos; David B Darr; Kristalyn Gallagher; Lee M Graves; Charles M Perou; Lisa A Carey; H Shelton Earp; Gary L Johnson
Journal:  Cancer Discov       Date:  2017-01-20       Impact factor: 39.397

3.  An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis.

Authors:  Smita Matkar; Paras Sharma; Shubin Gao; Buddha Gurung; Bryson W Katona; Jennifer Liao; Abdul Bari Muhammad; Xiang-Cheng Kong; Lei Wang; Guanghui Jin; Chi V Dang; Xianxin Hua
Journal:  Cancer Cell       Date:  2015-10-12       Impact factor: 31.743

4.  Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Authors:  Timothy J Stuhlmiller; Samantha M Miller; Jon S Zawistowski; Kazuhiro Nakamura; Adriana S Beltran; James S Duncan; Steven P Angus; Kyla A L Collins; Deborah A Granger; Rachel A Reuther; Lee M Graves; Shawn M Gomez; Pei-Fen Kuan; Joel S Parker; Xin Chen; Noah Sciaky; Lisa A Carey; H Shelton Earp; Jian Jin; Gary L Johnson
Journal:  Cell Rep       Date:  2015-04-09       Impact factor: 9.423

5.  Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

Authors:  Elias E Stratikopoulos; Meaghan Dendy; Matthias Szabolcs; Alan J Khaykin; Celine Lefebvre; Ming-Ming Zhou; Ramon Parsons
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

6.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

7.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962
  7 in total
  1 in total

1.  Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.

Authors:  Marisa A Fuse; Christine T Dinh; Jeremie Vitte; Joanna Kirkpatrick; Thomas Mindos; Stephani Klingeman Plati; Juan I Young; Jie Huang; Annemarie Carlstedt; Maria Clara Franco; Konstantin Brnjos; Jackson Nagamoto; Alejandra M Petrilli; Alicja J Copik; Julia N Soulakova; Olena Bracho; Denise Yan; Rahul Mittal; Rulong Shen; Fred F Telischi; Helen Morrison; Marco Giovannini; Xue-Zhong Liu; Long-Sheng Chang; Cristina Fernandez-Valle
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.